Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
SKLAR v. AMARIN CORPORATION PLC et al
Case Number:
3:13-cv-06663
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
-
April 27, 2016
Amarin Again Dodges Securities Suit Over Vascepa Denial
A New Jersey federal judge on Tuesday again dismissed a securities class action against biopharmaceuticals maker Amarin claiming it failed to fully inform investors about its progress during a failed bid to obtain approval for the expanded use of its fish oil drug Vascepa, saying no identified statements were materially false or misleading.
-
July 02, 2015
Amarin Ducks Securities Action Over Vascepa Denial
A New Jersey federal judge has dismissed a securities class action against biopharmaceuticals maker Amarin Corp. PLC that claimed it artificially inflated its stock price before a U.S. Food and Drug Administration panel denied expanding the use of its fish oil drug Vascepa to treat more adults with high triglycerides.